|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7763615||JAZZ||Ecteinascidin analogs for use as antitumour agents|| |
(1 year, 10 months from now)
|New Chemical Entity Exclusivity (NCE)||Jun 15, 2025|
|Orphan Drug Exclusivity (ODE)||Jun 15, 2027|
NCE-1 date: June, 2024
Market Authorisation Date: 15 June, 2020
Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic